More positives than negatives as far as trials are concerned. Funding and cash management I think we all share some concerns.
The unknown question is what results might be if the patients were not coming of multiple failed lines of treatment.
If Oncarlytics (CF33-CD19) similarly replicates and proves itself in combination with targeting therapies, the value of Oncarlytics becomes as much abt what it means for the sales of the other targeting therapies. I'd say a door into the other 90% of the market will have a lot of eyes watching this space.
IMU Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)